Risk Factors Update Summary

• Increased debt: Outstanding indebtedness of approximately $8.8 billion as of December 31, 2023, may impact financial condition and operations.
• Cyberattacks on IT systems could result in exposure of critical data or disruption of operations.
• We may incur additional costs before approvals, affecting business. This may result in decreased profitability.
• Revenues generated outside the US increased from $4.7 billion in 2022 to $8 billion in 2023.
• Patent protection: Loss of market exclusivity for key products could adversely affect business and cash flow.
• Increased tariffs and costs due to international trade tensions may adversely affect financial condition.
• Increased revenues outside the US now represent 76% of total revenues, down from 77%.
• Changes in tax laws globally, including a global minimum tax, may negatively impact effective tax rates.
• We are responsible for significant indemnification obligations, including antitrust litigation, which could be material.
• Our indemnity obligations to Merck may result in substantial income tax liability.
• Potential impact from the armed conflict between Ukraine and Russia may adversely affect business.
• Regulatory challenges: Subject to extensive regulations globally, non-compliance may result in sanctions and impact operations.
• Reliance on third parties for key aspects of business poses risks of non-compliance and penalties.
• Certain provisions may prevent or delay acquisitions, potentially affecting stock price and liquidity.
• Our ability to pay dividends depends on financial condition, strategy, and cash generation.
• Exclusive forum provisions could limit stockholders' ability to obtain favorable judicial forums for disputes.
• Additional costs may be incurred resolving matters in other jurisdictions, adversely affecting business.